Tadalafil Lilly ICOS.

David P Rotella

Bristol-Myers Squibb Company, Hopewell Discovery Chemistry, Princeton, NJ 08543-5400, USA. david.rotella@bms.com

Current opinion in investigational drugs (London, England : 2000) 2003 Jan

filter terms:

Tadalafil is a phosphodiesterase type 5 inhibitor in development by Lilly ICOS for the potential treatment of erectile dysfunction. The compound will be marketed in North America and Europe by a collaboration formed by Eli Lilly & Co and ICOS Corp. Eli Lilly & Co has marketing rights in all other territories. Marketing approval in Europe was granted in November 2002, with launch expected in the first half of 2003. An approvable letter was issued by the FDA in April 2002, with a US launch anticipated in the first half of 2003.